ApoB: What You Need to Understand

The Scene

The patient in this scene is a composite. Names, ages, and circumstances are changed to protect privacy.

Michael is 51 years old. He is 5’10”, weighs 205 pounds, and carries most of his weight around his abdomen. His lipid panel comes back: LDL 108 mg/dL, HDL 38 mg/dL, triglycerides 210 mg/dL. His calculated 10-year ASCVD risk is 9.8%, just below the threshold his primary care physician uses to consider a statin. He is told his cholesterol is “borderline” and to lose some weight.

He has a coronary artery calcium scan, unprompted, on a Tuesday afternoon at an imaging center that advertises direct-pay scans for $99. The Agatston score comes back at 214. That is in the 85th percentile for his age and sex.

His primary care physician refers him to me.

I run his ApoB. It comes back at 124 mg/dL.

Here is what these three numbers tell me about Michael: his LDL-C of 108 mg/dL and his CAC of 214 are in apparent conflict. An LDL of 108 is below the statin threshold by most calculators. A CAC of 214 at 51 says there is extensive calcified plaque already present. The resolution of this conflict lives in the ApoB. Michael has a type of lipid profile common in insulin-resistant patients: his LDL particles are numerous but small and cholesterol-depleted. Each particle carries less cholesterol than average, so his LDL-C (which measures total cholesterol mass in LDL particles) is modestly raised. But his ApoB of 124 mg/dL reflects 124 mg of ApoB per deciliter, which translates to approximately 2.8 billion LDL particles per milliliter of blood. His particles are small, many, and atherogenic. His LDL-C is telling the wrong story.

Allan Sniderman at McGill has spent 30 years documenting this discordance. Michael is his prototypical patient. This article is the explanation Michael deserves.

What It Is

ApoB as a Molecule

Apolipoprotein B (ApoB) is a large protein that serves as the structural backbone of atherogenic lipoprotein particles. There are two forms: ApoB-100 (the full-length form, synthesized in the liver, present on VLDL, IDL, LDL, and Lp(a)) and ApoB-48 (a truncated intestinal form present on chylomicrons). When clinicians refer to ApoB in cardiovascular risk assessment, they mean ApoB-100.

Each atherogenic lipoprotein particle carries exactly one molecule of ApoB-100. This is not a coincidence of physiology; it is structural: ApoB-100 wraps around the particle during its assembly in the liver, and because of its size and structure, only one can fit per particle. Therefore, measuring ApoB directly measures the number of atherogenic lipoprotein particles in the bloodstream.

Every LDL particle has one ApoB. Every IDL particle has one ApoB. Every VLDL remnant has one ApoB. Every Lp(a) particle has one ApoB (plus an Lp(a)-specific apolipoprotein, apo(a)). When you measure ApoB, you are measuring, with a single number, the total concentration of every particle that can enter the arterial wall, be retained there, and initiate an atherosclerotic lesion.

LDL-C, by contrast, measures the total mass of cholesterol contained within LDL particles. It does not count particles. In a patient whose LDL particles are uniformly cholesterol-enriched, LDL-C and particle number track together. In a patient with small, cholesterol-depleted LDL particles (the pattern Michael has), LDL-C underestimates particle number. This is the discordance problem.

Epidemiology: How Many People Have Discordance

The prevalence of ApoB-LDL-C discordance in the general population depends on the cut-offs used to define it. Studies consistently find that 20-30% of individuals have clinically meaningful discordance in one direction or another 5 / Solid 31827-5). The most dangerous form, the pattern Michael carries, is raised ApoB with normal or modestly raised LDL-C (sometimes called “hyperapobetalipo-proteinemia”). This pattern is strongly associated with insulin resistance, visceral obesity, type 2 diabetes, and the metabolic syndrome.

The other direction of discordance, raised LDL-C with lower-than-expected ApoB (few particles, each cholesterol-enriched), occurs in patients with large fluffy LDL, often genetically determined, and may carry lower-than-expected cardiovascular risk for the LDL-C level 5 / Solid .

The Mechanism

Why Particle Number, Not Cholesterol Mass, Determines Risk

The mechanism of atherogenesis begins with the entry of ApoB-containing particles into the arterial intima. The rate of entry is proportional to the concentration of particles in the plasma. Each particle that enters the intima carries its ApoB molecule into the vessel wall. That ApoB molecule, through LDL receptor-independent binding to arterial proteoglycans, anchors the particle in the intima where it undergoes oxidative modification and initiates foam cell formation (as described in PLAQ-001).

The concentration of particles (not the cholesterol load per particle) determines how many events of this kind occur per unit time. A million small LDL particles enter the intima just as many times as a million large LDL particles, but the small particles each carry less cholesterol. The LDL-C measurement in the patient with small particles therefore understates the particle-driven atherogenic exposure 5 / Solid .

The analogy Sniderman uses: if you want to know how much freight is moving across a bridge, counting trucks is more accurate than weighing the total cargo. LDL-C measures total cargo. ApoB counts trucks.

The Insulin Resistance Phenotype

Michael’s pattern (raised ApoB, high-normal or modestly raised LDL-C, raised triglycerides, low HDL-C) is the lipid signature of insulin resistance. The mechanism:

In insulin-resistant states, hepatic glucose uptake is impaired and the liver responds by producing excess VLDL (packaged with triglycerides and ApoB). The VLDL overproduction drives up circulating VLDL and its catabolic products, IDL and LDL. Simultaneously, CETP (cholesterol ester transfer protein) exchanges triglycerides from VLDL for cholesterol in LDL and HDL particles, producing triglyceride-rich, cholesterol-depleted LDL that is then hydrolyzed by hepatic lipase into small, dense LDL particles 5 / Solid .

Small, dense LDL particles are particularly atherogenic because:

1. They are more easily retained by proteoglycans in the arterial intima than large buoyant LDL
2. They have reduced affinity for the LDL receptor, prolonging their plasma half-life
3. They are more susceptible to oxidative modification
4. They penetrate endothelial junctions more readily due to their smaller size

The result in Michael: his ApoB of 124 mg/dL reflects more atherogenic particle burden than his LDL-C of 108 would suggest. His CAC of 214 is the biological record of that burden over the preceding years.

Non-LDL Atherogenic Particles

ApoB captures not only LDL particles but all atherogenic particles. In a patient with hypertriglyceridemia, VLDL remnant particles (IDL and larger LDL remnants) accumulate and contribute substantially to ApoB. The Copenhagen General Population Study and other large cohort studies have confirmed that VLDL remnants are independently atherogenic 5 / Solid . LDL-C does not capture these remnant particles. ApoB does.

In patients with Lp(a), the Lp(a) particle carries its own ApoB molecule. When Lp(a) is significantly raised (above 100 mg/dL, approximately above the 75th percentile), the Lp(a)-associated ApoB makes a non-trivial contribution to total ApoB. ApoB does not distinguish Lp(a) ApoB from LDL ApoB, which is a minor limitation of ApoB in very high Lp(a) states.

How We Diagnose It

Ordering and Interpreting ApoB

ApoB is ordered as a simple blood test through any standard laboratory. It is not a specialty test. LabCorp, Quest Diagnostics, and all major hospital laboratories measure ApoB directly by immunoturbidimetric or nephelometric assay. The test does not require fasting, though fasting is conventionally done when drawn as part of a lipid panel.

Reference ranges: The traditional laboratory reference range for ApoB (below 130 mg/dL) is population-derived and not clinically meaningful for cardiovascular risk. Risk-appropriate targets differ by clinical context:

The Canadian Cardiovascular Society was among the first major guideline bodies to formally incorporate ApoB targets into clinical recommendations 5 / Solid . The European Society of Cardiology 2019 guidelines explicitly recommend ApoB as an alternative to LDL-C for risk assessment and as a treatment target 5 / Solid .

In the United States, the 2018 ACC/AHA guidelines acknowledge ApoB as a risk-refining tool but stop short of recommending it as the primary treatment target, reflecting a more conservative approach to changing established clinical practice 5 / Solid . This position is increasingly viewed by lipidologists as out of step with the evidence.

ApoB vs LDL Particle Number

An alternative measurement of particle number is LDL-P (LDL particle number), measured by NMR spectroscopy (NMR LipoProfile, LabCorp). LDL-P and ApoB provide complementary information: LDL-P captures only LDL particles, while ApoB captures all atherogenic particles. For most clinical purposes, ApoB is the preferred metric because of its broader scope (capturing remnants and Lp(a)-associated particles), its standardization across laboratories, its direct measurement (not derived), and its lower cost compared to NMR panels 5 / Solid .

The Evidence

Sniderman and the EPPIC-CHD Analysis

The definitive clinical evidence for ApoB superiority over LDL-C as a cardiovascular risk predictor comes from a series of large epidemiological analyses, the largest of which is the EPPIC-CHD (Etude de Prévention Primaire de l’Infarctus Coronaire; this term covers the collaborative analyses of ApoB versus LDL-C as predictors of coronary events).

Sniderman AD et al. performed an individual patient data meta-analysis using data from the Prospective Studies Collaboration and multiple cohort studies, directly comparing the ability of ApoB and LDL-C to predict cardiovascular events. The central finding: when ApoB and LDL-C are concordant (i.e., both high or both low), the two measures predict risk equally well. When they are discordant, ApoB predicts risk more accurately than LDL-C 5 / Solid 31827-5). This is the formal proof of the clinical importance of discordance.

Ference and the Mendelian Randomization Data

Brian Ference’s pivotal Mendelian randomization analyses have been central to the ApoB debate. In a 2017 paper, Ference et al. used naturally randomized genetic instruments for LDL-C, ApoB, triglycerides, and HDL-C to determine which lipoprotein measure causally predicts coronary disease 5 / Solid .

The results: ApoB, LDL-C, and non-HDL-C were all causally associated with coronary disease. When ApoB and LDL-C were simultaneously included in the same model, ApoB fully mediated the association of LDL-C with coronary disease, but LDL-C did not fully mediate the association of ApoB. This means ApoB is the more proximate causal driver. The mechanism is clear: it is the particle itself (ApoB-containing) that enters the arterial wall, not the cholesterol it carries.

Ference’s 2020 study further clarified the hierarchy: in a meta-analysis of genetic studies representing over 800,000 individuals, each 10-mg/dL lower ApoB concentration was associated with a 4-6% lower risk of coronary disease, with a consistent causal association 5 / Solid .

The INTERHEART Study: ApoB/ApoA1 Ratio in Global Context

The INTERHEART study, a case-control study of 15,152 MI cases and 14,820 controls across 52 countries, evaluated nine modifiable risk factors for their contribution to population-attributable risk for MI 5 / Solid 17018-9). The ApoB/ApoA1 ratio was the strongest lipid-related predictor of MI across all regions studied, outperforming LDL-C, total cholesterol, and total cholesterol/HDL ratio.

This is particularly important because INTERHEART included populations in South Asia, sub-Saharan Africa, China, and Latin America where the atherogenic dyslipidemia phenotype (raised ApoB with modestly raised LDL-C) is common and where LDL-C alone dramatically underestimates risk.

The Walldius Stockholm Data: 20 Years of Longitudinal ApoB Evidence

Walldius G and colleagues at the Karolinska Institute followed 175,553 patients in Stockholm for up to 20 years, documenting the relationship between ApoB and cardiovascular events. This dataset, one of the largest and longest lipid-outcome databases in existence, consistently confirmed that ApoB predicts fatal MI more accurately than LDL-C in both men and women, and that the ApoB/ApoA1 ratio is the strongest lipid-based predictor of cardiovascular mortality 5 / Solid 05415-7; and 20-year follow-up analysis, 10.1371/journal.pone.0009629).

The Walldius dataset also established that women derive equal or greater predictive information from ApoB relative to LDL-C compared to men, a finding relevant to the clinical underestimation of cardiovascular risk in women.

ApoB Reduction With Statins and PCSK9 Inhibitors

Statin trials have historically been analyzed by LDL-C reduction, but secondary analyses of ApoB changes in these trials consistently show that ApoB reduction tracks more closely with clinical benefit than LDL-C reduction when the two diverge.

In the FOURIER trial (evolocumab added to statin therapy), ApoB fell from approximately 80 mg/dL to approximately 47 mg/dL, a 41% reduction 5 / Solid . LDL-C fell from 92 mg/dL to 30 mg/dL, a 67% reduction. The relatively smaller ApoB reduction reflects the fact that some LDL-C reduction is achieved by reducing the cholesterol content per particle as well as particle number. The clinical benefit (15% relative risk reduction in MACE over 2.2 years) is more consistent with the ApoB reduction magnitude than the LDL-C magnitude, which was proportionally much larger.

The Patient Experience

The Conversation About ApoB

When I tell Michael his ApoB is 124 mg/dL and explain what it means, his initial response is confusion: “You said my LDL was 108, which isn’t that bad. Now you’re telling me my ApoB of 124 is concerning. How can there be a difference?”

The explanation I use: imagine LDL particles as delivery trucks carrying cholesterol (cargo). Your LDL-C number tells me the total weight of cargo. Your ApoB tells me the number of trucks. When trucks carry normal-sized loads, both numbers track together. When trucks are smaller and carry less, the total cargo weight goes down but the number of trucks is unchanged. More trucks on the highway means more traffic, more wear on the road, and more risk of accidents. Your trucks are carrying less cholesterol than average, so your LDL-C looks modestly raised. But there are actually a lot of trucks. Your ApoB tells me the true traffic count.

Michael’s expression changes: “So the normal LDL test has been missing something.”

Yes. For some patients, it has.

What to Do With an Elevated ApoB

The clinical action follows from the risk tier:

For Michael, with an ApoB of 124, a CAC of 214 at age 51, and no current statin therapy, the clinical decision is straightforward: he meets criteria for statin initiation on multiple grounds (CAC above 100 is a guideline-supported indication for high-intensity statin in intermediate-risk patients; his ApoB of 124 is well above the 80 mg/dL target for high-risk patients). The goal: bring his ApoB below 80 mg/dL, which will likely require high-intensity statin therapy. The LDL-C target that corresponds to ApoB below 80 in a patient with his particle size distribution is approximately 70-85 mg/dL.

Decisions and Trade-Offs

Should ApoB Replace LDL-C as the Primary Target?

The argument for replacing LDL-C with ApoB as the primary treatment target is scientifically sound 5 / Solid 31827-5). ApoB is the more causally proximate measure of atherogenic particle burden, it is more accurate in patients with discordance, it is a direct measurement (not a calculation), and it is a single number that captures all atherogenic particles.

The practical arguments for keeping LDL-C:

• All major statin trial eligibility and endpoints were defined by LDL-C; changing targets requires recalibrating the entire clinical evidence base in the minds of practitioners
• LDL-C is familiar to both clinicians and patients; the communication value of a familiar number is not trivial
• LDL-C and ApoB are highly correlated in the majority of patients (concordant cases), so in population terms, most clinical decisions are the same regardless of which metric is used

The practical resolution: use LDL-C as the primary metric, supplement with ApoB when the clinical picture is inconsistent (as with Michael), when metabolic syndrome or insulin resistance raises the probability of discordance, or as part of a full cardiovascular risk assessment. This is the current practice at most specialty lipid programs.

When to Measure ApoB in Clinical Practice

Current evidence supports measuring ApoB in:

• Patients with metabolic syndrome, visceral obesity, or diabetes (high probability of discordance)
• Patients with raised triglycerides (triglycerides above 150 mg/dL raise the suspicion of insulin-resistant dyslipidemia)
• Patients whose LDL-C appears inconsistent with their clinical risk or imaging findings
• Patients on statin therapy whose LDL-C is at goal but who continue to have events (treatment failure assessment)
• As part of a preventive cardiology evaluation (e.g., SDE Audit)

The cost of an ApoB measurement is approximately $15-40 at standard laboratories. It is covered by most major insurance plans when ordered for dyslipidemia or cardiovascular risk assessment.

The SDE Synthesis

ApoB is one of the five numbers at the core of the SDE thesis, alongside Lp(a), coronary artery calcium score, VO2max, and fasting insulin. It is in this set not because it is the most famous lipid marker, but because it is the most accurate one for the population most likely to be missed by standard screening: the insulin-resistant patient with a “normal” LDL who presents with a high CAC and wonders why.

The SDE argument is that the standard lipid panel, ordered once at an annual physical and interpreted against population reference ranges, is an inadequate tool for individual cardiovascular risk stratification. An LDL of 108 mg/dL with an ApoB of 124 mg/dL and a CAC of 214 is not the same clinical situation as an LDL of 108 mg/dL with an ApoB of 82 mg/dL and a CAC of 0. The standard panel cannot distinguish these two patients. ApoB, combined with CAC, can.

Sniderman’s decades of work on particle discordance, Ference’s Mendelian randomization analyses, Walldius’s Stockholm cohort data, and the INTERHEART global findings collectively build an evidentiary case that is stronger than most single-drug clinical trials. The case is not for a new drug. It is for an existing, cheap, standardized blood test that most clinicians do not routinely order.

Every patient in the SDE program receives an ApoB measurement. Not as a novelty. As a standard of care.

The goal for Michael is not to tell him he is fine when he is not. The goal is to give him a number that explains his CAC, a target that is meaningful for his specific lipid phenotype, and a treatment plan that addresses the actual biological problem: too many atherogenic particles crossing his arterial walls per unit time.

The truck-and-cargo analogy will not appear in the New England Journal. But it will stay with Michael for the rest of his life, and that matters more.

Article ID: SDE-F-PLAQ-003 | Lane: Plaque | Author: Dr. Job Mogire, MD FACP FACC | Carle Foundation Hospital | Status: Draft | Voice Audit: Pending

Extended MARQUEE Content: The Complete ApoB Evidence Base

Ference et al. 2020: The Definitive Mendelian Randomization for ApoB

The most systematic Mendelian randomization analysis of ApoB’s causal role in coronary artery disease was published by Ference BA et al. in the European Heart Journal in 2020. This analysis used genetic variants that specifically affect ApoB concentration through LDL receptor-dependent and receptor-independent pathways to separate the effects of ApoB from LDL-C. 5 / Solid

The key finding: in fully adjusted models, ApoB was a better predictor of coronary disease than either LDL-C or non-HDL-C. Among patients with discordant LDL-C and ApoB, coronary risk tracked with ApoB rather than LDL-C. In the group with high ApoB but low LDL-C (the insulin resistance phenotype), risk was raised to the level predicted by the ApoB. In the group with high LDL-C but lower ApoB (large, cholesterol-enriched particles), risk was lower than LDL-C would predict.

This analysis directly supports using ApoB as the superior atherogenic marker in patients with metabolic syndrome, insulin resistance, raised triglycerides, or other conditions that dissociate LDL-C from LDL particle number.

The Walldius Stockholm Study: 20-Year Follow-Up

The Stockholm Heart Epidemiology Program (SHEEP) conducted by Walldius GK and Jungner I provided some of the earliest large-scale evidence for ApoB superiority in predicting MI. 5 / Solid 06714-X) Their 20-year prospective analysis of 175,553 men and women found that the ApoB/ApoA-I ratio was the single best predictor of MI risk across all age, sex, and risk factor subgroups: better than LDL-C, non-HDL-C, total cholesterol, or HDL-C.

The ratio (ApoB/ApoA-I) captures simultaneously the atherogenic particle burden (numerator) and the reverse cholesterol transport capacity (denominator). A patient with high ApoB and low ApoA-I has atherogenic lipoproteins overwhelming the system’s capacity to return cholesterol from tissues, creating net cholesterol accumulation in arterial walls. The Walldius data contributed to the INTERHEART study’s inclusion of the apolipoprotein ratio as one of nine modifiable risk factors for MI across 52 countries. 5 / Solid 17018-9)

Sniderman’s Discordance Framework in Clinical Detail

Allan Sniderman at McGill University has been the most persistent and influential advocate for ApoB in clinical practice. His framework distinguishes three atherogenic patterns:

Pattern 1: Concordant elevation: LDL-C raised, ApoB raised in proportion. Large LDL particles, each carrying the expected cholesterol load. Risk is predicted accurately by LDL-C. These patients are captured adequately by standard LDL-C monitoring.

Pattern 2: Discordant: high ApoB, normal or borderline LDL-C: Small dense LDL, many particles with low individual cholesterol content. Michael in the Scene section has this pattern (LDL-C 108 mg/dL, ApoB 124 mg/dL). The LDL-C underestimates atherogenic risk. This is the pattern of insulin resistance, metabolic syndrome, type 2 diabetes, and hypertriglyceridemia. Prevalence in general cardiology practice: 20-30%. 5 / Solid 31827-5)

Pattern 3: Discordant: raised LDL-C, lower-than-expected ApoB: Large, cholesterol-enriched LDL. Each particle carries more cholesterol than average, producing raised LDL-C with fewer particles. Risk is lower than LDL-C predicts. This pattern may occur in genetic conditions producing large LDL (raised Lp(a) falsely raises calculated LDL-C in some assays; some LDLR mutation carriers; familial combined hyperlipidemia variants). These patients are not better served by ApoB in the direction of identifying additional risk: but ApoB confirms their true particle burden is lower than LDL-C suggests.

ApoB Treatment Targets in Current Guidelines

The 2021 ESC/EAS Dyslipidaemia Guidelines recommend ApoB as an alternative measurement to LDL-C for assessing atherogenic risk and treatment response, and provide specific ApoB targets parallel to LDL-C targets:

The 2018 ACC/AHA guidelines acknowledge ApoB as an alternative to LDL-C for monitoring treatment response but do not specify ApoB targets, recommending a 50% or greater reduction in LDL-C as the primary treatment metric. 5 / Solid

Extended Mechanism: ApoB Across the Lipoprotein Spectrum

One ApoB Per Atherogenic Particle

The defining biochemical fact about ApoB is its stoichiometry: each VLDL, IDL, LDL, and Lp(a) particle contains exactly one ApoB molecule. No more, no less. This is why ApoB concentration in mg/dL is a direct measure of atherogenic particle number: one milligram of ApoB per deciliter corresponds to approximately 4 million VLDL+IDL+LDL+Lp(a) particles per milliliter.

This stoichiometry is maintained throughout the lipoprotein metabolism cascade. A nascent VLDL secreted by the liver carries one ApoB. As VLDL loses triglycerides (through LPL activity in the periphery) and becomes IDL, then LDL, each descendant particle carries the same single ApoB molecule. The ApoB count in plasma therefore reflects the total number of atherogenic particles present at any moment, regardless of their size or cholesterol content.

ApoB and VLDL Remnants: The Triglyceride Connection

In patients with raised triglycerides, VLDL and its catabolic remnants (IDL) constitute a larger fraction of total ApoB-containing particles. These remnant particles are smaller than VLDL but larger than LDL, and are independently atherogenic. They penetrate the arterial intima readily and are taken up by macrophages through different receptors than LDL.

ApoB captures both LDL particles and the VLDL/IDL remnants in a single measurement. In patients with triglycerides above 200 mg/dL, a significant proportion of total ApoB may come from remnant particles that LDL-C does not capture at all (or captures poorly through the Friedewald calculation). This is one reason why ApoB is particularly superior to LDL-C in hypertriglyceridemic patients. 5 / Solid

Extended SDE Synthesis: The ApoB Argument for the SDE Program

The ApoB article is a MARQUEE piece for the SDE thesis because it captures the central claim of the program: standard cardiovascular risk assessment is systematically incomplete, and the incompleteness has real clinical consequences.

Consider a population of 100 patients at a preventive cardiology clinic:

• 70 patients have concordant LDL-C and ApoB: standard LDL-C monitoring serves them adequately
• 20 patients have raised ApoB with normal or borderline LDL-C (the insulin resistance pattern): these patients are undertreated by LDL-C targets and have higher atherogenic exposure than their charts reflect
• 10 patients have raised LDL-C with lower ApoB (large fluffy LDL): these patients may be slightly overtreated, but the harm from this is small

For the 20 patients with discordant high ApoB, the SDE position is that their standard care is a systematic miss. They will reach their LDL-C targets on moderate-intensity statin therapy, their physician will consider them well managed, and they will continue to carry an raised ApoB that predicts higher-than-expected cardiovascular risk. The only way to identify them is to measure ApoB.

This is why Stop Dying Early measures ApoB in every patient evaluation. The number changes the clinical story for 1 in 5 patients seen. That is too large a proportion to miss.

SDE-F-PLAQ-003 | Expansion v1.1 | © sde / Dr. Job Mogire 2026

Extended Patient Experience: How to Present the ApoB Result to Patients

The Clinical Conversation

For most patients, ApoB is a new concept. The clinical conversation needs to explain:

1. What ApoB measures (the number of atherogenic particles, not the cholesterol load)
2. Why it matters (particle count predicts heart attack risk more precisely than cholesterol mass in patients with metabolic syndrome or insulin resistance)
3. What the number means for their specific risk (am I at target or not?)
4. What happens next (does this change the treatment plan?)

A clear patient-facing explanation: “Your LDL-C tells us how much cholesterol is being carried by the particles that build plaque. Your ApoB tells us how many particles are carrying that cholesterol. In your case, the particles are smaller than average and each one carries less cholesterol, so your LDL-C number looks better than it actually is. Your ApoB tells me the truth: you have more particles than we want, and each one is taking a trip through your arteries and potentially depositing cholesterol in the walls. That is why your CAC score showed plaque even though your LDL-C looked manageable.”

ApoB Monitoring During Treatment

Once statin therapy is initiated or intensified, ApoB monitoring at 4-12 weeks confirms the response. In Michael’s case (LDL-C 108 mg/dL, ApoB 124 mg/dL), initiating high-intensity statin therapy and adding ezetimibe at 3 months should target:

• LDL-C below 70 mg/dL (standard secondary prevention target given his premature atherosclerosis)
• ApoB below 80 mg/dL (corresponding ESC/EAS target for very high-risk patients)

If ApoB does not reach target despite LDL-C below 70 mg/dL (which can occur in patients with persistent insulin resistance), a PCSK9 inhibitor or bempedoic acid may be considered as the next therapeutic step.

Illinois ApoB Measurement Resources

ApoB measurement is available as a standard clinical laboratory test at Carle Health laboratory (Quest and LabCorp both offer ApoB in their standard panels). Most commercial insurance plans cover ApoB measurement when ordered for risk stratification in patients with metabolic syndrome, insulin resistance, or discordant LDL-C/non-HDL-C levels.

The 2018 ACC/AHA cholesterol guidelines and the 2021 ESC/EAS dyslipidaemia guidelines both endorse ApoB measurement, increasing insurance coverage authorization. Patients who are denied coverage should appeal with documentation of insulin resistance or metabolic syndrome: the primary clinical indication for ApoB when LDL-C appears at target but metabolic risk is raised.

SDE-F-PLAQ-003 | Expansion v2 | © sde / Dr. Job Mogire 2026

Extended Evidence Review: Mendelian Randomization and ApoB Causality

The Ference Meta-Analysis Architecture

Andrew Ference and colleagues have produced the most systematic Mendelian randomization evidence for ApoB causality. The key framework: using genetic variants that lower different atherogenic lipoprotein fractions: LDL-C variants (LDLR, PCSK9, NPC1L1), non-LDL variants that lower IDL/VLDL remnants (APOB itself, LPL variants), and variants that alter HDL-C: to dissect which fraction drives cardiovascular risk.

The central finding: genetic variants that lower ApoB predict lower cardiovascular risk proportional to the magnitude of ApoB reduction, regardless of which specific lipoprotein fraction the variant primarily affects. Variants that lower LDL-C without substantially changing ApoB (such as variants in CETP that raise HDL-C and lower LDL-C slightly) show much weaker cardiovascular risk reduction per unit of LDL-C change than variants that lower LDL-C proportionally with ApoB.

This finding directly supports the conclusion that ApoB, not the cholesterol mass within LDL, is the proximate atherogenic exposure. 5 / Solid

The Sniderman Three-Pattern Framework

Allan Sniderman of McGill University has described three distinct patterns of atherogenic dyslipidemia that ApoB measurement uniquely identifies. Understanding these three patterns is the clinical foundation for why ApoB measurement changes treatment decisions:

Pattern 1: Concordant LDL-C and ApoB (large LDL particles, low particle count for a given LDL-C): Classic hypercholesterolemia. LDL-C is raised and ApoB is proportionally raised. Standard LDL-C-guided management is appropriate. PCSK9 inhibitor or statin titration to LDL-C targets will simultaneously achieve ApoB targets. This is approximately 60-65% of patients.

Pattern 2: Raised ApoB with normal or borderline LDL-C (small dense LDL, high particle count despite normal cholesterol mass): Atherogenic dyslipidemia. The patient has an raised number of small, cholesterol-depleted LDL particles. LDL-C appears borderline or normal, but ApoB is above 100 mg/dL. Standard LDL-C-guided therapy may declare this patient at target when they are not. This is approximately 20-25% of patients, enriched among those with metabolic syndrome, insulin resistance, and hypertriglyceridemia.

Pattern 3: Raised LDL-C with normal ApoB (large buoyant LDL, high cholesterol mass per particle but low particle count): Relatively benign hypercholesterolemia. The patient has large, cholesterol-rich LDL particles but fewer total particles. LDL-C is raised but ApoB is at or near target. The evidence base (including polygenic MR) suggests these patients have lower atherogenic risk per unit of LDL-C elevation than Pattern 2. This is approximately 10-15% of patients.

The clinical value of knowing the pattern: it changes whether you treat, how aggressively you treat, and what target you use. ApoB is the instrument that reveals the pattern. LDL-C alone cannot distinguish Pattern 2 from Pattern 1. 5 / Solid

ApoB in Practice: Implementation at the SDE Clinic Level

Overcoming “My Insurance Doesn’t Cover ApoB”

One of the practical barriers to ApoB adoption is insurance coverage variability. Although ApoB measurement is listed in ACC/AHA guidelines, not all payers reimburse it as a routine measure. At Carle Foundation Hospital, ApoB is ordered routinely with the lipid panel for all patients in the preventive cardiology clinic, and the clinical team navigates coverage barriers as follows:

1. Document the indication: ApoB is covered when ordered for patients with metabolic syndrome, insulin resistance, or diabetes (where discordance is most clinically relevant)
2. For patients without a covered indication: the direct patient cost through Quest or LabCorp for an ApoB measurement is typically below $25: less than a copay for most patients
3. For patients in whom the result will definitively change management (e.g., determining whether to escalate from moderate to high-intensity statin): the clinical value justifies out-of-pocket cost

The goal in the SDE program: no preventive cardiology patient leaves the initial evaluation without an ApoB measurement. The first encounter may reveal discordance that changes the entire treatment trajectory.

ApoB Targets: The Number That Guides Treatment

The SDE program uses the following ApoB targets, aligned with ESC/EAS 2021 guidelines:

• Very high risk (established ASCVD, or FH with a second major risk factor, or diabetes with target organ damage): ApoB below 65 mg/dL
• High risk (10-year ASCVD risk above 10%, or severe individual risk factors): ApoB below 80 mg/dL
• Moderate risk (10-year ASCVD risk 5-10%): ApoB below 100 mg/dL
• Low risk (10-year ASCVD risk below 5%): ApoB below 130 mg/dL

These targets are aligned with the corresponding LDL-C targets but are used independently: a patient who reaches their LDL-C target but not their ApoB target (Pattern 2 discordance) continues to have the treatment escalated until ApoB target is met. A patient who overshoots their LDL-C target but has ApoB already at goal (Pattern 3 discordance) may not need further drug escalation.

The Next Step After ApoB: Non-HDL-C as an Accessible Surrogate

When ApoB is not available: in clinical settings where it is not routinely ordered or covered: non-HDL-C is the best clinically available surrogate. Non-HDL-C = Total cholesterol minus HDL-C. It captures the cholesterol content of all atherogenic particles: LDL, IDL, VLDL, and Lp(a). Non-HDL-C targets are 30 mg/dL higher than the corresponding LDL-C targets:

• Very high risk: non-HDL-C below 85 mg/dL (equivalent to LDL-C below 55 mg/dL)
• High risk: non-HDL-C below 100 mg/dL
• Moderate risk: non-HDL-C below 130 mg/dL

Non-HDL-C is superior to LDL-C for risk prediction but inferior to ApoB, because non-HDL-C is a cholesterol mass measure (still subject to the cholesterol content variation across particle sizes) rather than a particle count measure. In the SDE program, non-HDL-C serves as the second-best option when ApoB is unavailable.

The MARQUEE Statement: ApoB as the SDE Thesis

The SDE program’s clinical thesis, reduced to its core: most cardiovascular events that occur in patients who appear to be at goal by conventional LDL-C management are preventable. They are preventable because the patients were not, in fact, at goal on the metric that matters: ApoB: but only appeared at goal on the metric that is routinely measured.

The evidence for this thesis is strongest in the Sniderman discordance literature and the Ference Mendelian randomization work: LDL-C and ApoB disagree in approximately 20-25% of patients, and in those patients, ApoB is the stronger predictor. The clinical consequence of using LDL-C targets exclusively is systematic undertreatment of the insulin resistance/metabolic syndrome population: precisely the population that constitutes the largest share of preventable heart attacks in the United States.

SDE-F-PLAQ-003 | Expansion v3 | © sde / Dr. Job Mogire 2026